Organogenesis Holdings Inc. (ORGO): Net Income
$37.03M
Year ended 2025-12-31
-$84.16M
Trailing 12 months to 2026-06-30
+33.6%
3-year compound annual growth
+16.5%
5-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $37.03M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $861.0K | -82.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $4.95M | -68.2% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $15.53M | -83.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $94.20M | +446.6% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $17.23M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$38.71M | n/c | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$64.83M | n/m | 2021-03-16, From 2018-01-01 |
| 2017-12-31 | -$8.39M | n/m | 2020-03-09, From 2017-01-01 |
| 2016-12-31 | -$16.99M | n/a | 2019-03-18, From 2016-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $37.03M | n/m |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $456.91M | n/m |
| Insmed Inc (INSM) | 2025-12-31 | -$1.28B | n/m |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$225.68M | n/m |
| Mirum Pharmaceuticals, Inc. (MIRM) | 2025-12-31 | -$23.36M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $447.18M | n/m |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$732.94M | n/m |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$183.17M | n/m |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | -$25.55M | n/m |
Compare ORGO, HCM, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗